Latest Nitric oxide Stories
COCOA, Fla., April 11, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced that data on the NITROSYL Delivery System during Right Heart Catheterization (RHC) in subjects being evaluated for Orthotopic Heart Transplantation (OHT) and Left Ventricular Assist Device (LVAD) implantation has been selected for oral presentation at the International Society for Heart & Lung Transplantation (ISHLT) Annual...
Natural products industry executive Mark Becker credits his longevity in endurance racing to a comprehensive supplement regimen that includes the antioxidant Oligonol®. Hermosa Beach, CA (PRWEB) April 02, 2012 Long-time natural products industry executive Mark Becker has recently completed his 100th marathon – The Los Angeles Marathon on March 18, 2012. Mark completed the 26.2-mile course from Dodger Stadium to Santa Monica in 5:16:53. For almost 30 years, Mark has participated in...
HAMPTON, N.J., March 21, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the Center for Devices and Radiological Health (CDRH) branch of the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for compatibility of its INOMAX drug-delivery systems with three additional respiratory care devices. The INOMAX DS and the INOMAX DSIR have now been...
Many premature infants throughout the United States continue to receive inhaled nitric oxide (iNO) during their NICU stay, despite the lack of evidence to support its use. Whether or not a preemie will receive iNO treatment, when and for how long, varies greatly throughout the country, as its use in premature infants appears to be unstandardized. These are the findings of a Nationwide Children’s Hospital study appearing in the journal Pediatrics. Inhaled nitric oxide (iNO) is a...
HAMPTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD). The trial, which commenced in December 2009, enrolled its last patient six weeks ahead of schedule....
Boosts production of nitric oxide, reduces arterial stiffness Researchers studying why arteries stiffen in postmenopausal women have found a specific chemical cofactor that dramatically improves vascular function. Kerrie Moreau, Ph.D., Associate Professor of Medicine at the University of Colorado School of Medicine, discovered that BH4 or tetrahydrobiopterin plays a key role in arterial health of women. BH4 is a critical cofactor of the enzyme endothelial nitric oxide synthase or eNOS....
HAMPTON, N.J., Feb. 6, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 14th Annual BIO CEO & Investor Conference. Mr. Tasse's presentation will be given on Monday, February 13, 2012 at 3:30 p.m. EST in the Park South of the...
COCOA, Fla., Jan. 31, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded one new US patent for its proprietary Nitric Oxide generation and delivery technology. This patent brings the company's total issued US patents to ten. GeNO's tenth patent (8,083,997) on NITROSYL(TM) (nitric oxide) for inhalation concerns the conversion of nitrogen dioxide (NO2) to nitric oxide...
HAMPTON, N.J., Jan. 23, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse® DS drug-delivery system as a combination product for pulmonary arterial hypertension (PAH). An investigational new drug application...
COCOA, Fla., Jan. 19, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced the hiring of four new senior executives as well as two promotions. The additions add significant management talent and capability to the company. In a series of moves that more than doubles GeNO's executive management team, the company today announced the hiring of: Kurt Dasse, Ph.D., former President and Founder of...
